- Home
- / Alnylam
Alnylam
Stock Price
$284.7
2024-10-29
Market Capitalization
$36.5 B
2024-10-29
Revenue
$3.7 B
FY, 2025
Alnylam Summary
Company Summary
- Overview
- Alnylam is a biopharmaceutical company that develops ribonucleic acid interference (RNAi) therapeutics for hepatic porphyria, primary hyperoxaluria type 1 (PH1), cardiovascular, and polyneuropathy treatments. It offers patisiran, givosiran, lumasiran, and vutrisiran products.
- Type
- Public
- Status
- Active
- Founded
- 2002
- HQ
- Cambridge, MA, US | view all locations
- Website
- https://www.alnylam.com
- Cybersecurity rating
- ESG rating
- Sectors
Table of Contents
Key People
Pushkal Garg, Chief Medical Officer
Timothy Maines, Chief Technical Operations and Quality Officer
Jeff Poulton, Chief Financial Officer
LocationsView all
9 locations detected
Cambridge, MA HQ
United States
675 West Kendall Street
Taunton, MA
United States
20 Commerce Way
Paris, IDF
France
100 Av. de Suffren
Milan, Lombardia
Italy
Via Pola, 11
Tokyo, Tokyo
Japan
11th Floor of Pacific Century Place Marunouchi 1-11-1 Marunouchi, Chiyoda-ku
Amsterdam, NH
Netherlands
Cross Towers, 20e verdieping Antonio Vivaldistraat 150
Alnylam Financials
Summary Financials
- Revenue (Q1, 2026)
- $1.2B
- Gross profit (Q1, 2026)
- $959.7M
- Net income (Q1, 2026)
- $206.0M
- Cash (Q1, 2026)
- $1.7B
- EBIT (Q1, 2026)
- $268.6M
- Enterprise value
- $36.1B